GlassScriptPhysician profile
Jeffrey S Royce
NPI 1619910635
$889,991.74
in general payments reported to CMS, 2019-2025
31 companies · $65K in 2025
The $65K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202K · 2020: $150K · 2021: $179K · 2022: $166K · 2023: $62K · 2024: $65K · 2025: $65K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $140K · Consulting Fee: $32K · Travel and Lodging: $13K · Food and Beverage: $8,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $139,500.00 |
| Consulting Fee | $31,650.00 |
| Travel and Lodging | $13,299.43 |
| Food and Beverage | $8,161.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $319,198.58 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Allergan, INC. | $236,747.51 | 2019-2022 | |
| Amgen INC. | $133,324.63 | 2019-2024 | Aimovig |
| Lilly USA, LLC | $74,726.36 | 2019-2025 | Emgality, Reyvow |
| Biohaven Pharmaceutical Holding Company LTD. | $42,142.50 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $37,507.62 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $19,439.98 | 2019-2024 | Ajovy, Austedo Xr, Austedo |
| Impel Pharmaceuticals INC. | $14,051.78 | 2022-2023 | Trudhesa |
| Lundbeck LLC | $5,198.31 | 2020-2025 | Vyepti |
| Impel Pharmaceuticals LLC | $3,790.98 | 2025 | Trudhesa |
| Takeda Pharmaceuticals U.S.A., INC. | $1,310.37 | 2019 | |
| Pfizer INC. | $636.18 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $518.53 | 2019-2021 | |
| Axsome Therapeutics, INC. | $344.84 | 2025 | Symbravo |
| Tonix Medicines, INC. | $222.21 | 2024-2025 | Zembrace Symtouch |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $192.31 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $136.56 | 2019-2023 | Belsomra |
| Upsher-Smith Laboratories LLC | $125.14 | 2019-2021 | |
| Bausch Health US, LLC | $59.77 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $58.19 | 2020 | |
| Collegium Pharmaceutical, INC. | $57.68 | 2022 | |
| Promius Pharma LLC | $35.22 | 2019 | |
| Amneal Pharmaceuticals LLC | $30.77 | 2019-2020 | |
| Livanova USA, INC. | $21.82 | 2019 | |
| Idorsia Pharmaceuticals US INC | $21.69 | 2023 | Quviviq |
| Tersera Therapeutics LLC | $21.30 | 2019 | |
| Scilex Pharmaceuticals INC. | $17.12 | 2023 | Ztlido |
| Assertio Therapeutics, INC. | $15.27 | 2020 | |
| Arbor Pharmaceuticals, INC. | $13.47 | 2019 | |
| Amylyx Pharmaceuticals, INC. | $12.96 | 2023 | Relyvrio |
| Pernix Therapeutics Holdings, INC. | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Royce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.